

**PDF hosted at the Radboud Repository of the Radboud University
Nijmegen**

The following full text is a publisher's version.

For additional information about this publication click this link.

<http://hdl.handle.net/2066/26297>

Please be advised that this information was generated on 2022-08-25 and may be subject to change.

Total Synthesis of Brevetoxin B. 3. Final Strategy and Completion

K. C. Nicolaou,* F. P. J. T. Rutjes, E. A. Theodorakis, J. Tiebes, M. Sato, and E. Untersteller

Contribution from the Department of Chemistry, The Scripps Research Institute, 10666 N. Torrey Pines Road, La Jolla, California 92037, and Department of Chemistry and Biochemistry, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093

Received March 2, 1995*

Abstract: The final strategy for the total synthesis of brevetoxin B (1) according to the retrosynthetic analysis shown in Scheme 1 is described. Starting with the tetracyclic ring system 8 [DEFG], the construction of the C ring was accomplished via an intramolecular conjugate addition ($7 \rightarrow 13$). A hydroxy epoxide cyclization was then utilized for the formation of ring B ($6 \rightarrow 21$). Ring A was introduced via an intramolecular phosphonate ester–ketone condensation ($5 \rightarrow 27$) to produce, after side chain elaboration, the desired heptacyclic phosphonium iodide 4. Formation of the tricyclic aldehyde 3 [IJK] starting from diol 34 is also described. Wittig coupling of 3 and 4 followed by selective deprotection, hydroxy dithioketal cyclization, and radical desulfurization produced the undecacyclic system 48 representing the complete brevetoxin B skeleton ($46 \rightarrow 2 \rightarrow 47 \rightarrow 48$). Allylic oxidation of ring A ($48 \rightarrow 49$) followed by side chain elaboration of the K ring side chain ($49 \rightarrow 50 \rightarrow 51 \rightarrow 52$) led to the TBS protected brevetoxin B (52) which upon exposure to HF·pyridine treatment afforded natural brevetoxin B (1).

Introduction

In the preceding two papers^{1,2} we discussed explorations of strategies directed toward the total synthesis of brevetoxin B (1). These studies led to the evolution of the final and successful approach to this target molecule. Below we present full details of the direct route via which the total synthesis of brevetoxin B (1) was successfully accomplished.

Total Synthesis

The final approach to brevetoxin B (1) involved separate assembly of the ABCDEFG and IJK ring systems 4 and 3, their coupling, and final elaboration to the end. We will first address the construction of the more complex ABCDEFG segment 4.

Retrosynthetic Analysis and Strategy

The final synthetic strategy toward brevetoxin B (1) was designed on the basis of our experiences in the brevetoxin B project as described in the preceding papers^{1,2} and the retrosynthetic analysis shown in Scheme 1. According to the strategy, the final stages of the synthesis would entail (a) coupling of intermediates 3 and 4 by a Wittig reaction to give the corresponding (Z)-olefin, (b) deprotection to afford the hydroxy dithioketal 2, (c) ring closure to form the oxocene ring system, (d) desulfurization, and (e) functional group manipulation at the two ends of the molecule. The advanced ABCDEFG intermediate 4 was projected to be derived from DEFG lactone 9 (Scheme 1) by a sequence involving stepwise construction of the A, B, and C rings via ring closures as outlined in Scheme 1. The latter sequence was envisioned to involve (a) an

intramolecular phosphonate ester–ketone condensation ($5 \rightarrow 4$), (b) an intramolecular hydroxy epoxide cyclization ($6 \rightarrow 5$), (c) an intramolecular conjugate addition ($7 \rightarrow 6$), and (d) a Cr/Ni coupling reaction ($9 \rightarrow 8$). The syntheses of both lactone 9² and aldehyde 3^{3,4} starting with 2-deoxy-D-ribose (10) and D-mannose (11), respectively, have already been described. Unfolded below is the successful execution of this strategy and the completion of the total synthesis of brevetoxin B (1).

Construction of the ABCDEFG Ring System as Phosphonium Salt 4

The synthesis of the ABCDEFG segment 4 proceeded from the DEFG system 8 by constructing rings C, B, and A, one at a time and in that order. Thus, starting with aldehyde 8,² the CDEFG ring system 13 was constructed as summarized in Scheme 2. Condensation of 8 with the potassium derivative of $(\text{MeO})_2\text{P}(\text{O})\text{CH}_2\text{COOMe}$ [KHMDS, 18-crown-6, THF] furnished the α,β -unsaturated ester 12 in 99% yield. Selective removal of the triethylsilyl (TES) group from 12 using methanolic camphorsulfonic acid (CSA) led, quantitatively, to the hydroxy ester 7, which upon exposure to KH smoothly cyclized to afford the CDEFG ring system 13, together with its epimer at C*. On prolonged reaction time, however, this initially formed mixture was converted to a single product 13 (90% yield) bearing the side chain at the equatorial position. The structure of this intermediate was unambiguously confirmed by X-ray crystallographic analysis at a later stage (*vide infra*).⁵

With the crucial fusion of the C ring onto the growing polycyclic framework accomplished, we then proceeded to

* Address correspondence to this author at either The Scripps Research Institute or the University of California, San Diego.

† Abstract published in *Advance ACS Abstracts*, October 1, 1995.

(1) Nicolaou, K. C.; Hwang, C.-K.; Duggan, M. E.; Nugiel, D. A.; Abe, Y.; Bal Reddy, K.; DeFrees, S. A.; Reddy, D. R.; Awartani, R. A.; Rutjes, F. P. J. T.; Theodorakis, E. A. *J. Am. Chem. Soc.* 1995, 117, 10227–10238.


(2) Nicolaou, K. C.; Theodorakis, E. A.; Rutjes, F. P. J. T.; Sato, M.; Tiebes, J.; Xiao, X.-Y.; Hwang, C.-K.; Duggan, M. E.; Yang, Z.; Couladouros, E. A.; Sato, F.; Shin, J.; He, H.-M.; Bleckman, T. *J. Am. Chem. Soc.* 1995, 117, 10239–10251.

(3) Nicolaou, K. C.; Hwang, C.-K.; Duggan, M. E. *J. Am. Chem. Soc.* 1989, 111, 6682.


(4) Nicolaou, K. C.; Tiebes, J.; Theodorakis, E. A.; Rutjes, F. P. J. T.; Koide, K.; Sato, M.; Untersteller, E. *J. Am. Chem. Soc.* 1994, 116, 9371.

(5) This result is in accordance with the stereochemical outcome of similar cyclizations by Martin *et al.* which were carried out under kinetic conditions (NaH , Et_2O , -30°C) affording the cyclized product with the ester side chain in the axial position as a single isomer; see: Palázon, J. M.; Soler, M. A.; Ramirez, M. A.; Martin, V. S. *Tetrahedron Lett.* 1993, 34, 5467.

Scheme 1. Retrosynthetic Analysis and Strategic Bond Disconnections of Brevetoxin B (1): Third Generation Approach




Scheme 2. Construction of the CDEFG Ring System 13^a



^a Reagents and conditions: (a) 3.0 equiv of KHMDS, 0.2 equiv of 18-crown-6, 6.0 equiv of (MeO)₂P(O)CH₂CO₂Me, THF, 25 °C, 30 min, then add 8, 3 h, 25 °C, 99%; (b) 0.15 equiv of CSA, MeOH, 25 °C, 1 h, 100%; (c) 2.0 equiv of KH, THF, 25 °C, 20 min, 90%.


Scheme 3. Construction of the BCDEFG Ring System 22^a



^a Reagents and conditions: (a) 2.5 equiv of DIBALH, CH₂Cl₂, -78 °C, 30 min; quench with MeOH, 80% of 14 and 18% of 15; (b) 2.0 equiv of Ph₃P=CHCO₂Et, CH₂Cl₂, 25 °C, 12 h, 95%; (c) 3.0 equiv of DIBALH, CH₂Cl₂, -78 °C, 30 min, 96%; (d) 0.2 equiv of Ti(O-i-Pr)₄, 0.15 equiv of (+)-diethyl tartrate, 1.5 equiv of t-BuOOH (5–6 N in decane), CH₂Cl₂, -20 °C, 14 h, 99%; (e) 5.0 equiv of SO₃·pyridine, 10 equiv of Et₃N, CH₂Cl₂:DMSO (4:1), 0 °C, 5 h; (f) 4.0 equiv of NaHMDS, 5.0 equiv of CH₃PPh₃⁺Br⁻, THF, 0 °C, 30 min, 80% (over 2 steps); (g) 1.5 equiv of TBAF, THF, 25 °C, 10 h, 100%; (h) 0.5 equiv of PPTS, CH₂Cl₂, 0 °C, 14 h; (i) 2.0 equiv of TBSOTf, 3.0 equiv of 2,6-lutidine, CH₂Cl₂, 0 °C, 15 min, 76% (2 steps).

migrated from the tertiary to the primary alcohol. After the following step, the latter compound could be recycled to 14 by silylation, selective desilylation at the primary oxygen, and Dess-Martin oxidation (80% overall yield). Condensation of aldehyde 14 with the stabilized phosphoranylidene Ph₃P=CHCO₂Et furnished selectively the *E* isomer 16 in 95% yield. DIBALH reduction of ester 16 furnished allylic alcohol 17 (96% yield).


install the next heterocycle in line, namely ring B, as shown in Scheme 3. Thus, DIBALH reduction of ester 13 furnished aldehyde 14 in 80% yield, together with the over-reduced product 15 (18%) (Scheme 3) in which the silyl group had

Scheme 4. Synthesis of Phosphonium Iodide 4^a

Sharpless asymmetric epoxidation⁶ of the latter compound (17) using (+)-diethyl tartrate as the chiral auxiliary gave hydroxy epoxide 18 in 99% yield as a single isomer. Oxidation of 18 with $SO_3\cdot pyr$ and olefination ($CH_3PPh_3^+Br^-$ –NaHMDS) of the resulting aldehyde (19) afforded epoxy olefin 20 in 80% overall yield. Finally, desilylation of 20 using TBAF in THF gave hydroxy epoxide 6 (100%), which upon exposure to PPTS in CH_2Cl_2 underwent smooth and selective ring closure to the expected BCDEFG ring system 21. Silylation of the latter compound with TBSOTf in the presence of 2,6-lutidine led to silyl ether 22 in 76% overall yield from 6. The cyclization of 6 to 21 was rather slow compared to the similar cyclizations which formed the F and G rings.⁷ Furthermore, activation of the epoxide with an ester substituted vinyl group (rather than the simple vinyl group shown in the scheme) was not sufficient to effect cyclization under acidic conditions.

The stage was now set for the introduction of the final ring (A) and the completion of the synthesis of the ABCDEFG ring system of brevetoxin B (1). Scheme 4 outlines the chemistry involved in achieving this goal. Ozonolysis of the terminal olefin in 22 followed by reductive workup with Ph_3P resulted in the quantitative formation of aldehyde 23. The latter compound (23) was subjected to addition of methylmagnesium chloride, and the resulting secondary alcohol was oxidized with Dess-Martin periodinane leading to methyl ketone 24 in 91%

(6) Katsuki, T.; Sharpless, K. B. *J. Am. Chem. Soc.* 1980, 102, 5976.
(7) Nicolaou, K. C.; Nugiel, D. A.; Couladouros, E.; Hwang, C.-K. *Tetrahedron* 1990, 46, 4517.


**Figure 1. ORTEP drawing of 33.**

overall yield for the two steps.^{3,7} Removal of the silyl group from 24 with TBAF in THF liberated the secondary alcohol 25 (90%), which was esterified with bromoacetyl chloride in the presence of pyridine, to furnish bromide 26 (81% yield). Exchange of the bromide with a phosphonate group [$(MeO)_3P$, $90^\circ C$] led to the formation of phosphonate 5 in high yield. After evaporation of the excess $(MeO)_3P$ and without further purification, crude 5 was subjected to intramolecular condensation in the presence of $i\text{-Pr}_2EtN$ and $LiCl$ ⁸ to furnish lactone 27 in 89% overall yield from 26, thus completing the ABCDEFG ring framework of brevetoxin B (1). The following tactic of converting the ring A lactone to its cyclic allylic ether counterpart (29) was designed as a defensive measure against possible side reactions in the pending phosphorane generation with $n\text{-BuLi}$. This objective was easily accomplished by DIBALH reduction, followed by further $BF_3\cdot Et_2O$ -catalyzed reduction with Et_3SiH of the resulting lactol (28, mixture of anomers), to afford compound 29 in 93% overall yield. In order to reach the targeted intermediate (4), the appendages of ring G needed to be modified, a task accomplished by the following sequence: (a) reduction with Li –liquid NH_3 to remove the benzyl ethers and produce diol 30 (92%); (b) selective monotosylation to afford primary tosylate 31 (79%); (c) exchange of the tosylate with iodide to give hydroxy iodide 32; (d) silylation with TMS-imidazole to furnish TMS iodide 33 (93% overall yield for two steps); and (e) reaction with excess PPh_3 (CH_3CN , $80^\circ C$) to afford the desired phosphonium salt 4 in 99% yield. Iodide 33, mp 192–193 °C (from CH_3CN), was subjected to X-ray crystallographic analysis (see ORTEP drawing, Figure 1), confirming its structure and those of its predecessors.

Coupling of the ABCDEFG Phosphonium Salt 4 with IJK Aldehyde 3 and Final Stages of the Synthesis

With the ABCDEFG phosphonium salt 4 at hand, we were now in a position to proceed with its coupling to the IJK aldehyde 3. The latter compound was synthesized in a straightforward manner from the previously described intermediate 34³ as summarized in Scheme 5.⁴ Thus, exposure of 34 to $CH_2=C(OMe)Me$ in the presence of CSA converted it to acetonide 35 (89%) which was desilylated by TBAF in THF affording primary alcohol 36 in 97% yield. Swern oxidation of the latter compound (36), followed by condensation of the resulting aldehyde with $Ph_3P=CHCOOMe$ furnished α,β -unsaturated ester 37 as a mixture of *E*:*Z* (ca. 4:1) isomers in 96% overall yield. This mixture was hydrogenated to its saturated counterpart with concomitant debenzylation leading to hydroxy ester 38 in quantitative yield. Reduction of the ester group in 38 with $LiAlH_4$ gave diol 39 (92% yield) which was subjected to sequential and selective silylation using $t\text{-BuPh}_2SiCl$ (TPSCl) and $t\text{-BuMeSiOTf}$ (TBSOTf) to afford bis(silyl ether) 41 (93% overall yield) via monosilyl ether 40. Removal of the acetonide group from 41 with CSA in CH_2Cl_2 : $MeOH$ (1:1) led to diol 42 (87%) which was selectively silylated with

(8) Senfield, A. P.; Masamune, S.; Roush, W. R.; Sakai, T. *Tetrahedron Lett.* 1984, 25, 2183.


Scheme 5. Construction of the UK Ring System Aldehyde 3^a

^a Reagents and conditions: (a) 2.4 equiv of CH₂=C(OMe)Me, 0.2 equiv of CSA, CH₂Cl₂, 0 °C, 4 h, 89%; (b) 2.0 equiv of TBAF, THF, 25 °C, 2 h, 97%; (c) 1.7 equiv of (COCl)₂, 2.2 equiv of DMSO, CH₂Cl₂, -78 °C, 0.5 h, then 5.5 equiv of Et₃N, 100%; (d) 2.0 equiv of Ph₃P=CHCO₂Me, CH₂Cl₂, 25 °C, 5 h, 96% ((E):(Z) = 4:1); (e) H₂, Pd(OH)₂, EtOAc, 25 °C, 48 h, 100%; (f) 2.0 equiv of LiAlH₄, THF, 0 °C, 15 min, 92%; (g) 1.1 equiv of TPSCl, 2.0 equiv of Et₃N, 0.05 equiv of DMAP, CH₂Cl₂, 25 °C, 6 h, 93%; (h) 2.0 equiv of TBSOTf, 3.0 equiv of 2,6-lutidine, CH₂Cl₂, 0 °C, 0.5 h, 100%; (i) 0.2 equiv of CSA, CH₂Cl₂:MeOH (1:1), 0 °C, 2 h, 87%; (j) 1.0 equiv of TBSCl, 2.0 equiv of imidazole, DMF, 0 °C, 1 h, 94%; (k) 2.0 equiv of NMO, 0.05 equiv of TPAP, CH₃CN, 25 °C, 1 h, 96%; (l) 3.0 equiv of EtSH, 1.1 equiv of Zn(OTf)₂, CH₂Cl₂, 25 °C, 3 h, then 0.2 equiv of CSA, MeOH, 25 °C, 1 h, 74%; (m) 5.0 equiv of SO₃·pyridine, 10 equiv of Et₃N, CH₂Cl₂:DMSO (1:1), 0 °C, 1.5 h, 92%.

TBSCl, furnishing compound 43 (94% yield). The oxidation of 43 to ketone 44 was accomplished with *N*-methylmorpholine *N*-oxide (NMO) and tetra-*n*-propylammonium perruthenate (TPAP)⁹ catalyst in 96% yield, while dithioketal formation from 44 proceeded smoothly in the presence of EtSH and Zn(OTf)₂ to afford, after mild acid treatment, compound 45 (74% yield). Finally, oxidation of the primary alcohol in the latter compound (45) with SO₃·pyr complex resulted in the formation of the desired dithioketal aldehyde 3 in 92% yield.

Generation of the ylide from phosphonium salt 4 using *n*-BuLi in the presence of HMPA in THF followed by addition of aldehyde 3 resulted in the formation of the (*Z*)-olefin 46 (*J*_{cl} = 10.7 Hz), which upon exposure to PPTS in CH₂Cl₂-MeOH lost its TMS group selectively, furnishing hydroxy dithioketal 2 (75% overall yield for the two steps) (Scheme 6). A byproduct in this Wittig reaction was the α,β -unsaturated aldehyde corresponding to 3 from which a molecule of EtSH had been eliminated, leading, in turn, to partial ylide quenching and regeneration of phosphonium salt 4. The latter was recycled, thus increasing the yield of the product olefin 46. Ring closure of hydroxy dithioketal 2 to the oxocene system 47 was effected, in 85% yield, by treatment with AgClO₄-NaHCO₃-SiO₂-4 Å

(9) For a review on TPAP oxidations, see: Ley, S. V.; Norman, J.; Griffith, W. P.; Marsden, S. P. *Synthesis* 1994, 639.

Scheme 6. Total Synthesis of Brevetoxin B (1)^a

^a Reagents and conditions: (a) 1.05 equiv of *n*-BuLi, 3.0 equiv of HMPA, THF, -78 °C, then 1.5 equiv of 3, 10 min; (b) 0.25 equiv of PPTS, CH₂Cl₂:MeOH (1:1), 25 °C, 30 min, 75% (over 2 steps); (c) 4.0 equiv of AgClO₄, 10.0 equiv of NaHCO₃, silica, 4 Å MS, CH₃NO₂, 25 °C, 40 h, 85%; (d) 10.0 equiv of Ph₃SnH, 0.1 equiv of AIBN, toluene, 110 °C, 3 h, 100%; (e) 5.0 equiv of PCC, benzene, 80 °C, 3 h, 85%; (f) 1.0 equiv of TBAF, THF, 25 °C, 13 h, 69%; (g) 3.0 equiv of Dess-Martin periodinane, CH₂Cl₂, 25 °C, 30 min, 100%; (h) 5.0 equiv of Me₂N-CH₂⁺I⁻, 20 equiv of Et₃N, CH₂Cl₂, 25 °C, 16 h, 83%; (i) HF·pyridine, CH₂Cl₂, 0 °C, 30 min, 91%.

MS in nitromethane at 25 °C.¹⁰ The stereochemistry of the ethylthio (EtS) group in 47 was assumed to be α , in agreement with a model system whose structure was firmly established earlier by X-ray crystallographic analysis.¹⁰ Reductive removal of the EtS group from 47 was achieved in quantitative yield and with complete stereocontrol [exclusive *trans* stereoselectivity, tentatively assigned by comparison with a truncated version of this compound]⁴ using Ph₃SnH-AIBN in toluene at

(10) Nicolaou, K. C.; Duggan, M. E.; Hwang, C.-K. *J. Am. Chem. Soc.* 1986, 108, 2468. Nicolaou, K. C.; Prasad, C. V. C.; Hwang, C.-K.; Duggan, M. E.; Veale, C. A. *J. Am. Chem. Soc.* 1989, 111, 5321.




Figure 2. ORTEP drawing of synthetic brevetoxin B (1).

110 °C. The latter stereochemistry was eventually confirmed by the successful synthesis of brevetoxin B (1) and its X-ray crystallographic analysis.

With the entire polycyclic ring framework of brevetoxin B (1) in place, all that remained to be done was the final functionalization of the two ends of the molecule. To this end, ring A was first oxidized with PCC¹¹ in benzene at 80 °C to afford, in 85% yield, lactone 49. Selective desilylation of the primary oxygen of the side chain using a stoichiometric amount of TBAF in THF afforded primary alcohol 50 (69% yield). Oxidation of the latter compound (50) with Dess-Martin periodinane furnished, quantitatively, aldehyde 51, which upon exposure to Eschenmoser's reagent ($\text{Me}_2\text{N}=\text{CH}_2^+\text{I}^-$)¹² gave enal 52 (83% yield). Finally, HF·pyridine in CH_2Cl_2 removed the silicon group from 52, furnishing brevetoxin B (1) in 91% yield. Synthetic brevetoxin B (1) crystallized from methanol in beautiful colorless crystals (mp 272 °C dec; lit. mp 270 °C dec)¹³ and exhibited identical physical and spectroscopic data with those of an authentic sample (TLC, HPLC, $[\alpha]^{22}\text{D}$, IR, ¹H and ¹³C NMR, mass spec).¹⁴ An X-ray crystallographic analysis of synthetic brevetoxin B (1) (see ORTEP drawing, Figure 2) completed the characterization of the synthetic material.

Conclusion

In this, and the preceding two articles^{1,2} we presented the total synthesis of brevetoxin B (1) as it unfolded over the 12-year period from 1983 to 1994. The final strategy was not the one originally designed, but rather, one that evolved as new synthetic technology and tactics were discovered and developed in response to encountered problems. This process eventually led to a synthesis of the target molecule consisting of 123 steps in total, containing a set of 83 steps as the longest linear sequence (2-deoxy-D-ribose → brevetoxin B (1)) with an average yield per step of 91%.^{15,16} Among the most significant discoveries and developments of this program are the following: (a) the regio- and stereospecific hydroxy epoxide openings to form functionalized tetrahydropyran systems;¹⁷ (b) the powerful hydroxy dithioketal cyclization to construct oxocene ring systems;¹⁸ (c) the bridging of macrodithionolactones to

bicyclic and polycyclic systems;¹⁸ (d) the photolytically-induced cyclization of dithionoesters to form oxepane systems;^{1,19} (e) the reductive, silicon-induced cyclization of hydroxy ketones to form oxepane systems;^{1,20} (f) the nucleophilic addition reactions of organometallic reagents to thionolactones;²¹ (g) the new Cr/Ni promoted coupling reaction between aldehydes and lactone-derived enol triflates;² and (h) the synthesis of the first stable 1,2-dithietane system, dithiatopazine, and its novel chemistry.²² Some of these methods were used in the final sequence, some were not. All of them, however, were worth inventing, encountering, and developing, since they provide new options and opportunities for explorations in other areas of chemistry. Finally, the sheer excitement of being able to devise, after a long and adventurous odyssey,²³ a suitable path to reach this complex target molecule was highly rewarding and worthwhile to all of us involved in this project. It is our hope that the reader will find the story equally worthwhile.²⁴

Experimental Section

General Techniques. For a description of general techniques, see the preceding paper in this issue.²

α,β -Unsaturated Ester 12. A solution of trimethyl phosphonoacetate (878 μL , 5.42 mmol) in THF (5 mL) was treated dropwise with potassium bis(trimethylsilyl)amide (5.42 mL of a 0.5 M solution in toluene, 2.71 mmol) and 18-crown-6 (20 mg, 0.07 mmol) at 25 °C. After stirring for 30 min, a solution of aldehyde 8 (822 mg, 0.904 mmol) in THF (2 mL) was added dropwise and the resulting solution was stirred for 3 h at 25 °C. The reaction mixture was diluted with ether (25 mL), washed with brine (25 mL), dried (MgSO_4), and filtered. Concentration and flash chromatography (silica, 10–40% ether in petroleum ether) afforded α,β -unsaturated ester 12 (867 mg, 0.898 mmol, 99%). 12: colorless foam; $R_f = 0.50$ (silica, 30% ether in petroleum ether); IR (film) ν_{max} 2953 (m), 2876 (m), 1726 (m), 1652 (w), 1462 (m), 1380 (m), 1256 (m), 1071 (s), 1014 (m), 836 (m), 733 (m) cm^{-1} ; $[\alpha]^{22}\text{D} + 4.9$ (c 1.0, CH_2Cl_2); ¹H NMR (500 MHz, CDCl_3) δ 7.33–7.25 (m, 10 H, ArH), 7.04 (d, $J = 15.6$ Hz, 1 H, —CH), 5.91 (d, $J = 15.6$ Hz, 1 H, —CH), 4.55 (d, $J = 11.6$ Hz, 1 H, CH_2Ph), 4.46 (s, 2 H, CH_2Ph), 4.37 (d, $J = 11.6$ Hz, 1 H, CH_2Ph), 3.71 (s, 3 H, CO_2CH_3), 3.65–3.58 (m, 3 H, OCH), 3.50 (bq, $J = 8.9$ Hz, 1 H, OCH), 3.39 (bt, $J = 9.3$ Hz, 1 H, OCH), 3.33 (dd, $J = 12.0, 3.5$ Hz, 1 H, OCH), 3.27–3.23 (m, 2 H, OCH), 3.06 (dd, $J = 11.6, 3.8$ Hz, 1 H, OCH), 2.13–2.0 (m, 3 H, CH), 2.03–1.89 (m, 4 H, CH), 1.83–1.49 (m, 6 H, CH), 1.42–1.40 (m, 2 H, CH), 1.38 (s, 3 H, CH_3), 1.26 (s, 3 H, CH_3), 1.25 (s, 3 H, CH_3), 1.19 (s, 3 H, CH_3), 1.00 (d, $J = 6.3$ Hz, 3 H, CH_3), 0.95 (t, $J = 8.0$ Hz, 9 H, $\text{Si}(\text{CH}_2\text{CH}_3)_3$), 0.92 (s, 9 H, *t*-Bu), 0.57 (q, $J = 8.0$ Hz, 6 H, $\text{Si}(\text{CH}_2\text{CH}_3)_3$), 0.11 (s, 3 H, SiCH_3), 0.10 (s, 3 H, SiCH_3); ¹³C NMR (125 MHz, CDCl_3) δ 167.4, 156.6, 138.5, 138.5, 128.3, 128.2, 127.7, 127.6, 127.5, 116.7, 87.5, 86.9, 85.3, 82.8, 78.1, 78.0, 77.0, 76.0, 74.2, 73.5, 73.3, 73.0, 71.0, 66.0, 51.4, 47.7, 40.3,

(18) Nicolaou, K. C.; Hwang, C.-K.; Duggan, M. E.; Reddy, B. K.; Marron, B. E.; McGarry, D. G. *J. Am. Chem. Soc.* 1986, 108, 6800. Nicolaou, K. C.; Hwang, C.-K.; Marron, B. E.; DeFrees, S. A.; Couladouris, E.; Abe, Y.; Carroll, P. J.; Snyder, J. P. *J. Am. Chem. Soc.* 1990, 112, 3040.

(19) Nicolaou, K. C.; Hwang, C.-K.; Nugiel, D. A. *Angew. Chem., Int. Ed. Engl.* 1988, 27, 1362.

(20) Nicolaou, K. C.; Hwang, C.-K.; Nugiel, D. A. *J. Am. Chem. Soc.* 1989, 111, 4136.

(21) Nicolaou, K. C.; McGarry, D. G.; Veale, C. A.; Somers, P. K. *J. Am. Chem. Soc.* 1987, 109, 2504. Nicolaou, K. C.; McGarry, D. G.; Somers, P. K.; Kim, B. H.; Ogilvie, W. W.; Yiannikouros, G.; Prasad, C. V. C.; Veale, C. A.; Hark, R. R. *J. Am. Chem. Soc.* 1990, 112, 6263.

(22) Nicolaou, K. C.; Hwang, C.-K.; Duggan, M. E.; Carroll, P. J. *J. Am. Chem. Soc.* 1987, 109, 3801. Nicolaou, K. C.; Hwang, C.-K.; DeFrees, S.; Stylianides, N. A. *J. Am. Chem. Soc.* 1988, 110, 4868. Nicolaou, K. C.; DeFrees, S. A.; Hwang, C.-K.; Stylianides, N.; Carroll, P. J.; Snyder, J. P. *J. Am. Chem. Soc.* 1990, 112, 3029.

(23) For a personal review, see: Nicolaou, K. C. *Angew. Chem., Int. Ed. Engl.* Submitted for publication.

(24) For a pedagogical account of the brevetoxin synthesis, see: Nicolaou, K. C.; Sorensen, E. J. *Classics in Total Synthesis*; VCH Publishers: Weinheim, in press.

(11) For a similar example, see: Bonadies, F.; DiFabio, R. *J. Org. Chem.* 1984, 49, 1647.

(12) Schreiber, J.; Maag, H.; Hashimoto, N.; Eschenmoser, A. *Angew. Chem., Int. Ed. Engl.* 1971, 10, 330. Takano, S.; Inomata, K.; Samizu, K.; Tomita, S.; Yanase, M.; Suzuki, M.; Iwabuchi, Y.; Sugihara, K. *Chem. Lett.* 1989, 1283.

(13) Lin, Y.-Y.; Risk, M.; Ray, S. M.; Van Engen, D.; Clardy, J.; Golik, J.; James, J. C.; Nakanishi, K. *J. Am. Chem. Soc.* 1981, 103, 6773.

(14) We thank Drs. D. G. Baden and R. E. Gawley for a sample of natural brevetoxin B (1).

(15) Nicolaou, K. C.; Theodorakis, E. A.; Rutjes, F. P. J. T.; Tiebes, J.; Sato, M.; Untersteller, E.; Xiao, X.-Y. *J. Am. Chem. Soc.* 1995, 117, 1171.

(16) Nicolaou, K. C.; Rutjes, F. P. J. T.; Theodorakis, E. A.; Tiebes, J.; Sato, M.; Untersteller, E. *J. Am. Chem. Soc.* 1995, 117, 1173.

(17) Nicolaou, K. C.; Duggan, M. E.; Hwang, C.-K.; Somers, P. K. *J. Am. Chem. Soc., Chem. Commun.* 1985, 1359. Nicolaou, K. C.; Prasad, C. V. C.; Somers, P. K.; Hwang, C.-K. *J. Am. Chem. Soc.* 1989, 111, 5330. Nicolaou, K. C.; Prasad, C. V. C.; Somers, P. K.; Hwang, C.-K. *J. Am. Chem. Soc.* 1989, 111, 5335.

Lactone 27. A mixture of the crude phosphonate **5** (250 mg, 0.274 mmol), *N,N*-diisopropylethylamine (121 μ L, 0.96 mmol), and lithium chloride (40 mg, 0.96 mmol) in CH₃CN (3 mL) was stirred at 25 °C for 3 h. The mixture was diluted with ether (50 mL), washed with brine (25 mL), and dried (MgSO₄). Filtration, concentration, and flash chromatography (silica, 50→100% ether in petroleum ether) gave the lactone **27** (200 mg, 0.254 mmol, 89% (2 steps)). **27:** colorless foam; R_f = 0.35 (silica, 70% ether in petroleum ether); IR (film) ν_{max} 2942 (s), 2873 (s), 1731 (s), 1638 (w), 1457 (m), 1380 (m), 1270 (m), 1233 (m), 1066 (s), 956 (m), 880 (m), 737 (m), 703 (m) cm⁻¹; [α]²²_D +4.9 (c 1.0, CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃) δ 7.33–7.25 (m, 10 H, ArH), 5.73 (bs, 1 H, —CH), 4.54 (d, J = 11.6 Hz, 1 H, CHPh), 4.46 (s, 2 H, CH₂Ph), 4.37 (d, J = 11.6 Hz, 1 H, CHPh), 4.26 (bd, J = 10.8 Hz, 1 H, CHC—), 4.00 (dt, J = 11.1, 4.6 Hz, 1 H, CHOC(O)), 3.70–3.56 (m, 4 H, OCH), 3.37 (dd, J = 8.3, 5.2 Hz, 1 H, OCH), 3.33 (dd, J = 11.9, 3.5 Hz, 1 H, OCH), 3.28–3.24 (m, 1 H, OCH), 3.13–3.07 (m, 4 H, OCH), 2.30–2.26 (m, 1 H, CH), 2.16–2.06 (m, 3 H, CH), 2.01–1.63 (m, 10 H, CH), 1.96 (s, 3 H, CH₃), 1.55 (bt, J = 11.7 Hz, 1 H, CH), 1.40 (bt, J = 11.7 Hz, 1 H, CH), 1.30 (s, 3 H, CH₃), 1.29 (s, 3 H, CH₃), 1.25 (s, 3 H, CH₃), 1.20 (s, 3 H, CH₃), 1.03 (d, J = 7.0 Hz, 3 H, CH₃); ¹³C NMR (125 MHz, CDCl₃) δ 163.6, 161.1, 138.5, 138.4, 128.2, 128.2, 127.6, 127.5, 127.4, 115.5, 88.0, 87.3, 85.4, 83.9, 83.5, 78.9, 78.1, 77.8, 76.5, 74.6, 73.4, 73.3, 73.0, 71.0, 68.3, 66.0, 44.6, 40.3, 40.2, 37.9, 35.3, 33.1, 30.0, 29.6, 29.4, 28.8, 21.4, 20.2, 18.4, 17.5, 17.3, 15.7; HRMS, calcd for C₄₇H₆₂O₁₀Cs (M + Cs⁺) 919.3394, found 919.3399.

Allylic Ether 29. A solution of the lactone **27** (200 mg, 0.254 mmol) in CH₂Cl₂ (2 mL) was treated with diisobutylaluminum hydride (0.38 mL of a 1.0 M solution in CH₂Cl₂, 0.38 mmol) at -78 °C. After stirring for 30 min at -78 °C, the reaction was quenched with MeOH (1 mL), diluted with EtOAc (25 mL), and washed with aqueous saturated sodium potassium tartrate (25 mL). The water layer was extracted with EtOAc (2 × 25 mL) and the combined organic layers were dried (MgSO₄), filtered, and concentrated to give the crude lactol **28**. The crude lactol **28** (0.254 mmol) was dissolved in CH₂Cl₂ (2 mL) and treated with triethylsilane (202 μ L, 1.27 mmol) and boron trifluoride etherate (31 μ L, 0.254 mmol) at -10 °C. After stirring at -10 °C for 30 min, the reaction was quenched with triethylamine (1 mL), diluted with ether (25 mL), and washed with brine (25 mL). Drying (MgSO₄), filtration, concentration, and flash chromatography (silica, 50→100% ether in petroleum ether) gave the allylic ether **29** (145 mg, 0.188 mmol) and monodebenzylated products (34 mg, 0.05 mmol). Combined yield: 0.24 mmol, 93%. **29:** colorless foam; R_f = 0.60 (silica, 50% ether in petroleum ether); IR (film) ν_{max} 2937 (m), 2866 (m), 1456 (m), 1377 (m), 1072 (s), 1023 (m), 737 (m), 697 (m) cm⁻¹; [α]²²_D +21.3 (c 1.0, CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃) δ 7.33–7.25 (m, 10 H, ArH), 5.35 (bs, 1 H, —CH), 4.55 (d, J = 11.6 Hz, 1 H, CHPh), 4.46 (s, 2 H, CH₂Ph), 4.38 (d, J = 11.6 Hz, 1 H, CHPh), 4.25 (bd, J = 14.3 Hz, 1 H, OCHHCH—), 4.14 (bd, J = 15.1 Hz, 1 H, OCHHCH—), 3.98 (bd, J = 7.9 Hz, 1 H, OCHC—), 3.66–3.54 (m, 4 H, OCH), 3.37 (dd, J = 8.3, 5.2 Hz, 1 H, OCH), 3.33 (dd, J = 12.0, 3.4 Hz, 1 H, OCH), 3.29–3.20 (m, 2 H, OCH), 3.14 (dd, J = 12.3, 3.7 Hz, 1 H, OCH), 3.11–3.07 (m, 2 H, OCH), 2.14–2.07 (m, 3 H, CH), 2.02–1.90 (m, 4 H, CH), 1.85–1.61 (m, 8 H, CH), 1.71 (s, 3 H, CH₃), 1.53 (bt, J = 11.7 Hz, 1 H, CH), 1.41 (bt, J = 11.5 Hz, 1 H, CH), 1.31 (s, 3 H, CH₃), 1.27 (s, 3 H, CH₃), 1.25 (s, 3 H, CH₃), 1.20 (s, 3 H, CH₃), 1.04 (d, J = 7.0 Hz, 3 H, CH₃); ¹³C NMR (125 MHz, CDCl₃) δ 138.5, 138.5, 134.5, 128.3, 128.3, 127.7, 127.6, 127.5, 121.0, 88.0, 87.4, 85.3, 83.9, 80.2, 78.1, 77.9, 74.7, 73.7, 73.5, 73.3, 73.0, 71.0, 69.5, 66.9, 66.0, 45.0, 40.3, 40.2, 38.0, 35.4, 33.2, 31.0, 29.7, 29.5, 28.9, 28.1, 21.5, 20.3, 18.5, 17.5, 17.2, 16.2; HRMS, calcd for C₄₇H₆₂O₉Cs (M + Cs⁺) 905.3605, found 905.3588.

Diol 30. A solution of dibenzyl ether **29** (145 mg, 0.188 mmol) and monobenzylated side products (34 mg, 0.05 mmol) obtained above in THF (1 mL) was added dropwise at -78 °C to a dark blue solution of lithium (100 mg) in liquid ammonia (ca. 45 mL). After stirring at -78 °C for 1 h, the reaction was quenched with ammonium chloride (100 mg) and the ammonia was allowed to evaporate. The residue was taken up in EtOAc (25 mL), washed with brine (10 mL), dried (MgSO₄), filtered, concentrated, and subjected to flash chromatography (silica, 100% ether → 100% ethyl acetate) to give diol **30** (128 mg, 0.216 mmol, 92%). **30:** colorless foam; R_f = 0.30 (silica, 100% ethyl

acetate); IR (film) ν_{max} 3398 (m), 2935 (m), 2874 (m), 1458 (m), 1380 (m), 1270 (w), 1071 (s), 732 (m), 615 (m) cm⁻¹; [α]²²_D +44.1 (c 1.0, CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃) δ 5.33 (d, J = 1.2 Hz, 1 H, —CH), 4.23 (dq, J = 16.0, 2.1 Hz, 1 H, OCHHCH—), 4.11 (dq, J = 16.2, 2.1 Hz, 1 H, OCHHCH—), 3.95 (bd, J = 8.1 Hz, 1 H, OCHC—), 3.85–3.77 (m, 3 H, OCH), 3.54 (bq, J = 8.3 Hz, 1 H, OCH), 3.34 (dd, J = 8.3, 5.2 Hz, 1 H, OCH), 3.31 (dd, J = 12.0, 3.4 Hz, 1 H, OCH), 3.27–3.17 (m, 2 H, OCH), 3.12 (dd, J = 12.1, 3.4 Hz, 1 H, OCH), 3.10–3.05 (m, 2 H, OCH), 3.0–2.5 (bs, 2 H, 2 × OH), 2.12–2.04 (m, 3 H, CH), 2.02–1.96 (m, 2 H, CH), 1.92–1.86 (m, 1 H, CH), 1.83–1.70 (m, 5 H, CH), 1.68 (s, 3 H, CH₃), 1.66–1.58 (m, 4 H, CH), 1.51 (bt, J = 11.7 Hz, 1 H, CH), 1.44 (bt, J = 11.7 Hz, 1 H, CH), 1.29 (s, 3 H, CH₃), 1.26 (s, 6 H, 2 × CH₃), 1.24 (s, 3 H, CH₃), 1.01 (d, J = 7.0 Hz, 3 H, CH₃); ¹³C NMR (125 MHz, CDCl₃) δ 134.5, 121.0, 87.9, 87.6, 85.3, 83.9, 83.8, 80.2, 80.0, 78.0, 74.7, 73.9, 73.6, 73.3, 71.2, 69.5, 66.9, 59.2, 45.0, 43.7, 42.9, 37.9, 35.4, 33.2, 31.0, 29.4, 28.8, 21.5, 20.2, 18.5, 17.2, 16.2, 15.6; HRMS, calcd for C₃₃H₅₂O₉Na (M + Na⁺) 615.3509, found 615.3520.

Tosylate 31. A solution of diol **30** (128 mg, 0.216 mmol) and *p*-toluenesulfonyl chloride (162 mg, 0.864 mmol) in CH₂Cl₂/pyridine (10:1, 4 mL) was stirred at 25 °C for 12 h. The mixture was diluted with EtOAc (25 mL), washed with aqueous saturated ammonium chloride (20 mL), and dried (MgSO₄). Filtration, concentration, and flash chromatography (silica, 50→100% ether in petroleum ether → 100% EtOAc) gave a mixture of tosylate **31** (80 mg) and diol **30** (50 mg). The latter compound was recycled twice to give an additional amount of tosylate **31** (total yield: 128 mg, 0.171 mmol, 79%). **31:** colorless foam; R_f = 0.40 (silica, 70% ether in petroleum ether); IR (film) ν_{max} 3463 (w), 2945 (m), 2874 (m), 1458 (m), 1363 (m), 1177 (m), 1072 (s), 956 (m), 733 (m), 663 (m), 555 (m) cm⁻¹; [α]²²_D +39.1 (c 1.0, CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃) δ 7.77 (d, J = 8.0 Hz, 2 H, ArH), 7.33 (d, J = 8.0 Hz, 2 H, ArH), 5.33 (q, J = 1.4 Hz, 1 H, —CH), 4.26–4.11 (m, 4 H, OCH), 3.96 (bd, J = 7.8 Hz, 1 H, OCHC—), 3.71 (dd, J = 11.6, 5.4 Hz, 1 H, OCH), 3.53 (bq, J = 8.5 Hz, 1 H, OCH), 3.33 (dd, J = 8.4, 5.2 Hz, 1 H, OCH), 3.26–3.17 (m, 3 H, OCH), 3.12 (dd, J = 12.3, 3.7 Hz, 1 H, OCH), 3.07 (dd, J = 9.0, 2.4 Hz, 1 H, OCH), 3.03 (dd, J = 11.7, 3.8 Hz, 1 H, OCH), 2.44 (s, 3 H, CH₃), 2.12–2.07 (m, 3 H, CH), 2.00–1.96 (m, 2 H, CH), 1.94–1.87 (m, 2 H, CH), 1.82–1.72 (m, 3 H, CH), 1.69 (s, 3 H, CH₃), 1.67–1.58 (m, 5 H, CH), 1.51 (bt, J = 11.8 Hz, 1 H, CH), 1.40 (bt, J = 11.8 Hz, 1 H, CH), 1.27 (s, 3 H, CH₃), 1.25 (s, 3 H, CH₃), 1.17 (s, 3 H, CH₃), 1.15 (s, 3 H, CH₃), 1.01 (d, J = 7.0 Hz, 3 H, CH₃); ¹³C NMR (125 MHz, CDCl₃) δ 144.8, 134.5, 133.0, 129.8, 127.9, 121.0, 87.9, 87.5, 85.3, 83.9, 83.8, 80.2, 78.0, 74.7, 73.9, 73.6, 73.2, 70.7, 69.5, 66.9, 66.8, 58.4, 45.0, 43.8, 39.3, 37.9, 35.4, 33.2, 31.0, 29.4, 28.6, 21.6, 21.5, 20.1, 18.5, 18.4, 17.1, 16.4, 16.2; HRMS, calcd for C₄₀H₅₈O₁₁SCs (M + Cs⁺) 879.2754, found 879.2717.

Iodide 33. A solution of tosylate **31** (42 mg, 0.055 mmol) in acetone (1 mL) was treated with sodium iodide (42 mg, 0.28 mmol) and heated at 60 °C for 5 h. The resulting solution was diluted with ether (25 mL), washed with aqueous saturated sodium thiosulfate (20 mL), and dried (MgSO₄). Filtration and concentration gave the crude iodo alcohol which was used directly for the next step. The iodo alcohol was dissolved in CH₂Cl₂ (2 mL), treated with (trimethylsilyl)imidazole (41 μ L, 0.28 mmol), and stirred at 25 °C for 30 min. The mixture was diluted with ether (25 mL), washed with aqueous saturated ammonium chloride (20 mL), and dried (MgSO₄). Filtration, concentration, and flash chromatography (silica, 20→40% ether in petroleum ether) afforded the iodide **33** (41 mg, 0.053 mmol, 96%). **33:** colorless plates, mp 192–193 °C (acetonitrile); R_f = 0.85 (silica, 50% ether in petroleum ether); IR (film) ν_{max} 2950 (s), 2874 (s), 1458 (m), 1379 (m), 1256 (m), 1073 (s), 883 (m), 842 (m), 734 (m), 648 (w) cm⁻¹; [α]²²_D +39.1 (c 1.0, CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃) δ 5.33 (q, J = 1.5 Hz, 1 H, —CH), 4.23 (bd, J = 16.2 Hz, 1 H, OCHHCH—), 4.12 (bd, J = 16.2 Hz, 1 H, OCHHCH—), 3.95 (bd, J = 7.5 Hz, 1 H, CHC—), 3.65 (dd, J = 11.2, 5.4 Hz, 1 H, OCH), 3.54 (bq, J = 7.5 Hz, 1 H, OCH), 3.34 (dd, J = 8.3, 5.2 Hz, 1 H, OCH), 3.27–3.17 (m, 5 H, OCH), 3.12 (dd, J = 12.1, 3.5 Hz, 1 H, OCH), 3.10–3.06 (m, 1 H, OCH), 3.04 (dd, J = 11.6, 3.8 Hz, 1 H, OCH), 2.24–2.17 (m, 1 H, CH), 2.12–1.98 (m, 5 H, CH), 1.85–1.76 (m, 4 H, CH), 1.70–1.56 (m, 5 H, CH), 1.68 (s, 3 H, CH₃), 1.51 (bt, J = 11.7 Hz, 1 H, CH), 1.43 (bt, J = 11.6 Hz, 1 H, CH), 1.28 (s, 3 H, CH₃), 1.25 (s, 3 H, CH₃), 1.22 (s, 3 H,

1 H, —CH), 4.26 (d, $J = 10.8$ Hz, 1 H, OCHC—), 4.03–3.94 (m, 4 H, OCH), 3.88 (dd, $J = 8.9, 3.2$ Hz, 1 H, OCH), 3.81 (bs, 1 H, OCH), 3.55 (bq, $J = 7.7$ Hz, 1 H, OCH), 3.42–3.23 (m, 6 H, OCH), 3.13–3.02 (m, 4 H, OCH), 2.66 (bs, 1 H, OH), 2.45–2.26 (m, 4 H, CH), 2.21–2.08 (m, 4 H, CH), 2.05–1.43 (m, 16 H, CH), 1.96 (s, 3 H, CH₃), 1.29 (s, 3 H, CH₃), 1.29 (s, 6 H, 2 × CH₃), 1.22 (s, 3 H, CH₃), 1.17 (s, 3 H, CH₃), 1.02 (d, $J = 7.0$ Hz, 3 H, CH₃); ¹³C NMR (125 MHz, CDCl₃) δ 194.5, 163.7, 161.2, 147.7, 136.1, 135.1, 127.2, 115.6, 88.3, 87.6, 85.5, 84.0, 83.6, 80.1, 79.8, 79.0, 77.8, 77.3, 76.6, 76.2, 75.1, 74.7, 74.7, 74.0, 73.9, 71.5, 71.4, 69.4, 68.3, 63.3, 44.6, 41.2, 39.4, 38.0, 37.5, 35.3, 33.2, 31.9, 31.7, 30.3, 30.1, 29.5, 28.8, 22.0, 19.9, 18.5, 18.2, 17.3, 15.8, 13.8; HRMS, calcd for C₅₀H₇₀O₁₄Na (M + Na⁺) 917.4663, found 917.4622.

Acknowledgment. We thank Drs. Dee H. Huang (TRSI), Gary Siuzdak (TSRI), Raj Chadha (TSRI), George Furst (University of Pennsylvania), John Dykins (University of Pennsylvania), and Pat Carroll (University of Pennsylvania) for their superb NMR (D.H.H.; G.F.), mass spectroscopic (G.S.; J.D.), and X-ray crystallographic (R.C.; P.C.) assistance. This work was carried out at the University of Pennsylvania where the project started, the University of California, San Diego, and The Scripps Research Institute where the project was completed. This program was financially supported by the National

Institutes of Health, USA, by fellowships from The Netherlands Organization for Scientific Research (NWO) (F.P.J.T.R.), the Deutsche Forschungsgemeinschaft (J.T.), Unitika, Ltd. (MS), Rhone-Poulenc Rorer, S. A. (E.U.), the ALSAM Foundation (USA), Dainippon Pharm. Co., Ltd. (Japan), Glaxo, Inc. (USA), Hoffmann-La Roche (USA), Merck Sharp & Dohme (USA), Pfizer, Inc. (USA), Rhone-Poulenc Rorer (USA), Schering Plough (USA), and Smith Kline Beecham (USA).

Supporting Information Available: Experimental procedures and selected data for compounds 35–44, as well as X-ray crystallographic data for compounds 33 and 1, tables of anisotropic displacement coefficients and H atom coordinates, unit cell packing diagrams, stereo views, and torsion angles and mean plane equations (51 pages). Listing of structure factors (23 pages). This material is contained in many libraries on microfiche, immediately follows this article in the microfilm version of the journal, can be ordered from the ACS, and can be downloaded from the Internet; see any current masthead page for ordering information and Internet access instructions.

JA9506925